Department of Microbiology and Immunology, Medical School, University of Tampere, Finland.
Clin Exp Immunol. 2011 May;164(2):211-7. doi: 10.1111/j.1365-2249.2011.04354.x. Epub 2011 Mar 10.
Pentraxin 3 (PTX3) is a novel candidate immunoinflammatory marker that has been reported to be associated with cardiometabolic risk factors and to predict adverse outcomes in individuals with cardiovascular disease (CVD). Despite being a member of the same pentraxin protein family as C-reactive protein (CRP), PTX3 probably reflects different aspects of CVD pathogenesis. In this study, we assessed plasma PTX3 correlates and determinants in the Health 2000 Survey population, which comprised n = 403 insulin-resistant subjects, n = 845 hypercholesterolaemic subjects and n = 311 hypertensive subjects, all aged between 46 and 76 years. In insulin-resistant subjects the PTX3 concentration was found to correlate directly with age, pulse pressure and indoleamine 2,3-dioxygenase (IDO) enzyme activity and inversely with total and low-density lipoprotein (LDL) cholesterol. In hypercholesterolaemic subjects, the PTX3 concentration correlated directly with HDL cholesterol, systolic blood pressure and pulse pressure, whereas in hypertensive subjects, the PTX3 concentration correlated directly with systolic blood pressure, pulse pressure and IDO activity. No correlation was observed between the concentrations of PTX3 and CRP, adiposity indicators or indicators of subclinical atherosclerosis in any of the subject groups. PTX3 concentration variations were attributed to variations in LDL cholesterol and IDO activity in insulin-resistant subjects and to pulse pressure in hypercholesterolaemic and hypertensive subjects. These results indicate that, in individuals at high risk of CVD, the PTX3 concentration is associated with cardiovascular risk factors but not with subclinical atherosclerosis.
五聚素 3(PTX3)是一种新型候选免疫炎症标志物,据报道与心血管代谢危险因素相关,并可预测心血管疾病(CVD)患者的不良结局。尽管 PTX3 是 C 反应蛋白(CRP)的同一家族成员,但它可能反映了 CVD 发病机制的不同方面。在这项研究中,我们评估了 Health 2000 调查人群中血浆 PTX3 的相关性和决定因素,该人群包括 n = 403 例胰岛素抵抗患者、n = 845 例高胆固醇血症患者和 n = 311 例高血压患者,年龄均在 46 至 76 岁之间。在胰岛素抵抗患者中,PTX3 浓度与年龄、脉压和吲哚胺 2,3-双加氧酶(IDO)酶活性呈正相关,与总胆固醇和低密度脂蛋白(LDL)胆固醇呈负相关。在高胆固醇血症患者中,PTX3 浓度与高密度脂蛋白胆固醇、收缩压和脉压呈正相关,而在高血压患者中,PTX3 浓度与收缩压、脉压和 IDO 活性呈正相关。在任何一组患者中,PTX3 浓度与 CRP、肥胖指标或亚临床动脉粥样硬化指标之间均无相关性。PTX3 浓度的变化归因于胰岛素抵抗患者中 LDL 胆固醇和 IDO 活性的变化,以及高胆固醇血症和高血压患者中脉压的变化。这些结果表明,在 CVD 高危人群中,PTX3 浓度与心血管危险因素相关,但与亚临床动脉粥样硬化无关。